Gallaudet University, Washington, DC, USA.
School of Language, Education, and Culture, Gallaudet University, Washington, DC, USA.
Clin Trials. 2023 Oct;20(5):576-580. doi: 10.1177/17407745231177376. Epub 2023 May 26.
BACKGROUND/AIMS: This article discusses the barriers that prevent deaf people from participating in clinical trials and offers recommendations to overcome these barriers and ensure equal access to study participation.
Between April and May 2022, we conducted six focus groups with 20 deaf adults who use American Sign Language, all of whom had previous experience as research study participants. Focus group prompts queried community awareness of clinical trial opportunities, barriers and facilitators to deaf people's participation in clinical trials, and recommended resources to improve clinical trial access. This qualitative focus group data is supplemented by survey data gathered from 40 principal investigators and clinical research coordinators between November 2021 and December 2021. The survey queried researchers' prior experiences with enrolling deaf participants in clinical trials and strategies they endorse for enrollment of deaf participants in future clinical trials.
Focus group participants unanimously agreed that, compared to the general hearing population, deaf sign language users lack equivalent access to clinical trial participation. Reported barriers included lack of awareness of clinical trial opportunities, mistrust of hearing researchers, and refusal by clinical trial staff to provide accessible communication (e.g. denial of requests for sign language interpreters). Survey data from 40 principal investigators and clinical research coordinators corroborated these barriers. For example, only 2 out of 40 survey respondents had ever enrolled a deaf person in a clinical trial. Respondents indicated that the most helpful strategies for including deaf sign language users in future clinical trials would be assistance with making recruitment information accessible to deaf sign language users and assistance in identifying qualified interpreters to hire to help facilitate the informed consent process.
The lack of communication accessibility is the most common factor preventing deaf sign language users from participating in clinical trials. This article provides recommendations for hearing researchers to improve deaf people's access to clinical trials moving forward, drawing from mixed-methods data.
背景/目的:本文讨论了阻碍聋人参与临床试验的因素,并提出了克服这些障碍、确保他们平等参与研究的建议。
2022 年 4 月至 5 月,我们对 20 名使用美国手语的成年聋人进行了 6 次焦点小组讨论,他们都有过参与研究的经验。焦点小组的讨论提示询问了社区对临床试验机会的认知、聋人参与临床试验的障碍和促进因素,以及改善临床试验参与的建议资源。本次定性焦点小组数据由 2021 年 11 月至 12 月间收集的 40 名主要研究者和临床研究协调员的调查数据补充。调查询问了研究人员以前在招募聋人参与者参与临床试验方面的经验,以及他们在未来临床试验中招募聋人参与者的策略。
焦点小组的参与者一致认为,与一般听力人群相比,聋人手语使用者在参与临床试验方面的机会不平等。报告的障碍包括缺乏对临床试验机会的认识、对听力研究人员的不信任,以及临床试验工作人员拒绝提供无障碍沟通(例如拒绝手语翻译的请求)。40 名主要研究者和临床研究协调员的调查数据证实了这些障碍。例如,40 名调查受访者中只有 2 人曾在临床试验中招募过聋人。受访者表示,对聋人手语使用者参与未来临床试验最有帮助的策略将是协助使招募信息对聋人手语使用者可访问,以及协助确定合格的口译员以聘请来帮助促进知情同意过程。
沟通无障碍是阻碍聋人手语使用者参与临床试验的最常见因素。本文从混合方法数据中为听力研究人员提出了改善聋人参与临床试验的建议。